Fast Five Quiz: Myelodysplastic Syndromes-Related Anemia Refractory to Erythropoiesis-Stimulating Agents Reviewed by Rami Komrokji, MD

https://reference.medscape.com/viewarticle/mds-esa-refractory-anemia-2026a1000hc3?_gl=1*19oh2po*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTAxODc1NTU5LjE3ODM4NjY0NjYuMTc4Mzg2NzMzMg.. Myelodysplastic syndromes (MDS)-related anemia that is refractory to erythropoiesis-stimulating agents (ESAs) represents a clinically significant challenge. However, emerging therapies are reshaping treatment algorithms, transfusion strategies, and long-term quality-of-life outcomes.